Grifols (Grifols) Net Margin %

: 3.73% (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Grifols's Net Income for the three months ended in Sep. 2023 was $64 Mil. Grifols's Revenue for the three months ended in Sep. 2023 was $1,705 Mil. Therefore, Grifols's net margin for the quarter that ended in Sep. 2023 was 3.73%.

The historical rank and industry rank for Grifols's Net Margin % or its related term are showing as below:

GIKLY' s Net Margin % Range Over the Past 10 Years
Min: 0.9 Med: 12.78 Max: 15.35
Current: 3.49

GIKLY's Net Margin % is ranked worse than
51.03% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 3.76 vs GIKLY: 3.49

Grifols Net Margin % Historical Data

The historical data trend for Grifols's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

12.26

11.58

3.83

3.43

0.90

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Net Margin %																2.89	1.17	3.61	3.73	3.16

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Net Margin % distribution charts can be found below:

* The bar in red indicates where Grifols's Net Margin % falls into.

Grifols Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Grifols's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	64.684	/	7188.634
	=	0.90 %

Grifols's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	63.546	/	1704.89
	=	3.73 %

Grifols (OTCPK:GIKLY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Grifols Net Margin % Related Terms

Thank you for viewing the detailed overview of Grifols's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.